Skip to main content

Advertisement

SpringerLink
Log in

Do pleiotropic effects of statins beyond lipid alterations exist in vivo? What are they and how do they differ between statins?

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

The inhibition of cellular proliferation, the restoration of endothelial activity, the inhibition of platelet reactivity, and an antioxidant potential are only a few examples of pleiotropic effects of statins. This review analyzes the current knowledge on the pleiotropic properties of this class of drugs and examines the relevant data that support the presence of these effects in vivo. The favorable outcome of major trials of statins has indicated that pleiotropic factors indeed play a role in cardiovascular protection. In addition, recent data indicate that many pleiotropic effects influence mechanisms that belong to the extravascular compartment, as well. Perhaps, some of these properties may eventually justify additional indications for statins and improve the treatment of other diseases, including inflammation and cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West Of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301–1307.

    Article  PubMed  CAS  Google Scholar 

  2. Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patient with average cholesterol levels. N Engl J Med 1996, 335:1001–1009.

    Article  PubMed  CAS  Google Scholar 

  3. Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998, 279:1615–1622.

    Article  PubMed  CAS  Google Scholar 

  4. Buchwald H, Campos CT, Boen JR: Disease-free intervals after partial ileal bypass in patients with coronary heart disease and hypercholesterolemia: report from the program on the surgical control of the hyperlipidemias (POSCH). J Am Coll Cardiol 1995, 26:351–357.

    Article  PubMed  CAS  Google Scholar 

  5. Lipid Research Clinic Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results: 1. Reduction in incidence of coronary heart disease. JAMA 1984, 251:351–364.

    Article  Google Scholar 

  6. Laufs U, La Fata V, Plutzky J, et al.: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998, 97:1129–135.

    PubMed  CAS  Google Scholar 

  7. Brandes RP, Behra A, Lebherz C, et al.: Lovastatin maintains nitric oxide—but not EDHF-mediated endothelium-dependent relaxation in the hypercholesterolemic rabbit carotid artery. Atherosclerosis 1999, 142:97–104.

    Article  PubMed  CAS  Google Scholar 

  8. Endres M, Laufs U, Huang Z, et al.: Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. PNA S 1998, 95:8880–8885.

    Article  CAS  Google Scholar 

  9. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al.: Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998, 101:2711–2719.

    Article  PubMed  CAS  Google Scholar 

  10. Essig M, Nguyen G, Prie D, et al.: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ Res 1998, 83:683–690.

    PubMed  CAS  Google Scholar 

  11. Bellosta S, Bernini F, Ferri N, et al.: Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis. 1998, 137:S101-S109.

    Article  PubMed  CAS  Google Scholar 

  12. Colli S, Eligini S, Lalli M, et al.: Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arter Thromb Vasc Biol 1997, 17:265–272.

    CAS  Google Scholar 

  13. Muller C, Kiehl MG, van de Loo J, et al.: Lovastatin induces p21WAF1/Cip1 in human vascular smooth muscle cells: influence on protein phosphorylation, cell cycle, induction of apoptosis, and growth inhibition. Bioorg Med Chem Letters 1999, 3:63–68.

    CAS  Google Scholar 

  14. Corsini A, Bernini F, Quarato P, et al.: Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Cardiology 1996, 87:458–468.

    Article  PubMed  CAS  Google Scholar 

  15. Vrtovsnik F, Couette S, Prie D, et al.: Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21ras activated, AP-1-dependent pathway. Kidney Int 1997, 52:1016–1027.

    Article  PubMed  CAS  Google Scholar 

  16. Nakagawa H, Mutoh T, Kumano T, et al.: HMG-CoA reductase inhibitor-induced L6 myoblast cell death: involvement of the phosphatidylinositol 3-kinase pathway. FEBS Letters 1998, 438:289–292.

    Article  PubMed  CAS  Google Scholar 

  17. Jiang J, Roman RJ: Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension 1997, 30:968–974.

    PubMed  CAS  Google Scholar 

  18. Mitani H, Bandoh T, Ishikawa J, et al.: Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits. Br J Pharmacol. 1996, 119:1269–1275.

    PubMed  CAS  Google Scholar 

  19. Sposito AC, Mansur AP, Coelho OR, et al.: Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (Enalapril or Lisinopril). Am J Cardiol 1999, 83:1497–1499.

    Article  PubMed  CAS  Google Scholar 

  20. Farnier M, Davignon J: Current and future treatment of hyperlipidemia: the role of statins. Am J Cardiol 1998, 82:J3-J10.

    Article  Google Scholar 

  21. Corsini A, Bellosta S, Baetta R, et al.: New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999, in press.

  22. Kreuzer J, Bader J, Jahn L, et al.: Chemotaxis of the monocyte cell line U937: dependence on cholesterol and early mevalonate pathway products. Atherosclerosis 1991, 90:203–209.

    Article  PubMed  CAS  Google Scholar 

  23. Rudich SM, Mongini PK, Perez RV, et al.: HMG-CoA reductase inhibitors pravastatin and simvastatin inhibit human B-lymphocyte activation. Transpl Proc 1998, 30:992–995.

    Article  CAS  Google Scholar 

  24. Muldoon MF, Flory JD, Marsland A, et al.: Effects of lovastatin on the immune system. Am J Cardiol 1997, 80:1391–1394.

    Article  PubMed  CAS  Google Scholar 

  25. Katznelson S, Wang XM, Chia D, et al.: The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro. J Heart Lung Transplant 1998, 17:335–340.

    PubMed  CAS  Google Scholar 

  26. Kobashigawa JA, Katznelson S, Laks H, et al.: Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995, 333:621–627.

    Article  PubMed  CAS  Google Scholar 

  27. Bellosta S, Via D, Canavesi M, et al.: HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscl Thromb Vasc Biol. 1998, 18:1671–1678.

    PubMed  CAS  Google Scholar 

  28. Giroux LM, Davignon J, Naruszewicz M: Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. BBA 1993, 1165:335–338.

    PubMed  CAS  Google Scholar 

  29. Fisher JE, Rogers MJ, Halasy JM, et al.: Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. PNAS (USA) 1999, 96:133–138.

    Article  CAS  Google Scholar 

  30. Gujarro C, Blanco-Colio LM, Ortego M, et al.: 3-hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998, 83:490–500.

    Google Scholar 

  31. Dimitroulakos J, Nohynek D, Backway KL, et al.: Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach. Blood 1999, 93:1308–18.

    PubMed  CAS  Google Scholar 

  32. Tan A, Levrey H, Dahm C, et al.: Lovastatin induces fibroblast apoptosis in vitro and in vivo. A possible therapy for fibroproliferative disorders. Am J Resp & Crit Care Med. 1999, 159:220–227.

    CAS  Google Scholar 

  33. Shipman CM, Croucher PI, Russell RG, et al.: The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998, 58:5294–5297.

    PubMed  CAS  Google Scholar 

  34. Rao S, Lowe M, Herliczek TW, et al.: Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 1998, 17:2393–2402.

    Article  PubMed  CAS  Google Scholar 

  35. Rubins JB, Greatens T, Kratzke RA, et al.: Lovastatin induces apoptosis in malignant mesothelioma cells. Am J Resp Crit Care Med 1998, 157:1616–1622.

    PubMed  CAS  Google Scholar 

  36. Crick DC, Andres DA, Danesi R, et al.: Geranylgeraniol overcomes the block of cell proliferation by lovastatin in C6 glioma cells.

  37. Lee SJ, Ha MJ, Lee J, et al.: Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21 (WAF1/CIP1) in human prostate carcinoma cells. J Biol Chem 1998, 273:10618–10623.

    Article  PubMed  CAS  Google Scholar 

  38. Marcelli M, Cunningham GR, Haidacher SJ, et al.: Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res 1998, 58:76–83.

    PubMed  CAS  Google Scholar 

  39. Muller C, Bockhorn AG, Klusmeier S, et al.: Lovastatin inhibits proliferation of pancreatic cancer cell lines with mutant as well as with wild-type K-ras oncogene but has different effects on protein phosphorylation and induction of apoptosis. Int J Oncol 1998, 12:717–723.

    PubMed  CAS  Google Scholar 

  40. Hunakova L, Sedlak J, Sulikova M, et al.: Human multidrug-resistant (MRP,p190) myeloid leukemia HL-60/ADR cells in vitro: resistance to the mevalonate pathway inhibitor lovastatin. Neoplasma 1997, 44:366–369.

    PubMed  CAS  Google Scholar 

  41. Ghosh PM, Mott GE, Ghosh-Choudhury N, et al.: Lovastatin induces apoptosis by inhibiting mitotic and post-mitotic events in cultured mesangial cells. Biochem Biophys Acta 1997, 1359:13–24.

    Article  PubMed  CAS  Google Scholar 

  42. Cui Q, Wang GJ, Su CC, et al.: The Otto Aufranc Award. Lovastatin prevents steroid induced adipogenesis and osteonecrosis. Clin Orthop Rel Res 1997, 344:8–19.

    Google Scholar 

  43. Soma MR, Baetta R, De Renzis MR, et al.: In vivo enhanced antitumor activity of carmustine [N,N′-bis(2-chloroethyl)-N-nitrosourea] by simvastatin. Cancer Res 1995, 55:597–602.

    PubMed  CAS  Google Scholar 

  44. Melichar B, Ferrandina G, Verschraegen CF, et al.: Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines. Clin Cancer Res 1998, 4:3069–3076.

    PubMed  CAS  Google Scholar 

  45. Scandinavian Simvastatin Survival Group. Randomized trial of cholesterol lowering in 4444 patients with coronary disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383–1389.

    Article  Google Scholar 

  46. MacMahon S, Sharpe N, Gamble G, et al.: Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID. Circulation 1997, 97:1784–1790.

    Google Scholar 

  47. Corsini A, Pazzucconi F, Pfister P, et al.: Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin. Lancet 1996, 348:1584.

    Article  PubMed  CAS  Google Scholar 

  48. Tsuda Y, Satoh K, Kitadai M, et al.: Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Atherosclerosis. 1996, 22:225–233.

    Article  Google Scholar 

  49. Kohno M, Murakawa K, Yasunari K, et al.: Improvement of erythrocyte deformability by cholesterol-lowering therapy with pravastatin in hypercholesterolemic patients. Metabolism 1997, 46:287–291.

    Article  PubMed  CAS  Google Scholar 

  50. Mercuri M, Bond MG, Sirtori CR, et al.: Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: The Carotid Atherosclerosis Italian Ultrasound Study. Am J Med 1996, 101:627–634.

    Article  PubMed  CAS  Google Scholar 

  51. Aviram M, Hussein O, Rosenblat M, et al.: Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy. J Cardiol Pharmacol 1998, 31:39–45.

    Article  CAS  Google Scholar 

  52. Gould KL, Martucci JP, Goldberg DI, et al.: Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. Circulation 1994, 89:1530–1538.

    PubMed  CAS  Google Scholar 

  53. Prospective Studies Collaboration: Cholesterol, diastolic blood pressure, and stroke, 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 1995, 346:1647–1653.

    Article  Google Scholar 

  54. Thibault A, Samid D, Tompkins AC, et al.: Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996, 2:483–491.

    PubMed  CAS  Google Scholar 

  55. Larner J, Jane J, Laws E, et al.: A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am J Clin Oncol 1998, 21:579–583.

    Article  PubMed  CAS  Google Scholar 

  56. Hamelin BA, Turgeon J: Hydrophilicity/lipophilicitity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. TiPS. 1998, 19:26–37.

    PubMed  CAS  Google Scholar 

  57. Newby AC, Libby P, van der Wal AC. Plaque instability—the real challenge for atherosclerosis research in the next decade? Cardiovasc Res 1999, 41:321–322.

    Article  PubMed  CAS  Google Scholar 

  58. Libby P, Aikawa M: New insights into plaque stabilisation by lipid lowering. Drugs 1998, 56(Suppl 1):9–13.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Pharmacological Sciences, University of Milan, Via Balzaretti, 9, I-20133, Milan, Italy

    Agostino Faggiotto MD & Rodolfo Paoletti MD, PhD

Authors
  1. Agostino Faggiotto MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rodolfo Paoletti MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Faggiotto, A., Paoletti, R. Do pleiotropic effects of statins beyond lipid alterations exist in vivo? What are they and how do they differ between statins?. Curr Atheroscler Rep 2, 20–25 (2000). https://doi.org/10.1007/s11883-000-0091-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-000-0091-3

Keywords

Search

Navigation